Case Studies

How AlphaMeld engagements show up in real R&D programs.

Anonymized examples of the kinds of work AlphaMeld scientists run for Pharma R&D — target shortlists, hypothesis validation packages, safety benchmarks. Real engagements are written up under NDA; what follows is illustrative of shape, scope, and time-to-deliverable.

EXAMPLEAll cases below are illustrative and anonymized.

EXAMPLEOncology

Top-10 Pharma · illustrative

Compressed an oncology target shortlist from quarters to weeks.

Problem

An R&D team needed a defensible target shortlist for a solid-tumor indication where prior screens had stalled at the prioritization step.

Approach

Knowledge-graph extraction across literature, trials, and omics datasets; AlphaMeld scientists ran agent-driven verification and authored mechanistic rationales for each finalist.

Outcome

A ranked list with full evidence trails delivered ahead of the program decision gate. The team advanced two targets into validation.

37Targets ranked

8Finalists with full dossiers

6 weeksTime to delivery

EXAMPLERare disease

Mid-cap biotech · illustrative

Validated a rare-disease asset hypothesis end-to-end before BD review.

Problem

A late-stage discovery hypothesis needed a defensible validation package — efficacy, safety, endpoint fit — before a partnership conversation.

Approach

Hypothesis dossier built against the AlphaMeld knowledge graph; standard-of-care comparison and population-level signal scan run by AlphaMeld scientists.

Outcome

A complete validation package, evidence-linked and reviewable, delivered ahead of the BD window.

12Endpoints reviewed

9Comparator therapies analyzed

5 weeksTime to delivery

EXAMPLESafety / portfolio

Pharma R&D · illustrative

Benchmarked a portfolio's safety profile against a live competitor cohort.

Problem

An R&D leader wanted a defensible read on how the safety profile of an in-house program compared to an evolving competitor cohort across multiple indications.

Approach

Pathway risk review and on-/off-target liability mapping; competitor benchmark assembled from trial registries, AE signals, and KG-traversed pathway evidence.

Outcome

A standalone benchmark report used to inform an internal portfolio review and shape downstream trial design choices.

14Competitor programs benchmarked

23Pathways reviewed

4 weeksTime to delivery

Get started

Ready to compress your discovery timelines?

See AlphaMeld run a live target-discovery workflow on your therapy area in 30 minutes.

Request a demo →Try ChatAlphaMeld